Literature DB >> 24872111

Breast cancer in China.

Lei Fan1, Kathrin Strasser-Weippl2, Jun-Jie Li1, Jessica St Louis3, Dianne M Finkelstein4, Ke-Da Yu5, Wan-Qing Chen6, Zhi-Ming Shao5, Paul E Goss7.   

Abstract

The health burden of cancer is increasing in China, with more than 1·6 million people being diagnosed and 1·2 million people dying of the disease each year. As in most other countries, breast cancer is now the most common cancer in Chinese women; cases in China account for 12·2% of all newly diagnosed breast cancers and 9·6% of all deaths from breast cancer worldwide. China's proportional contribution to global rates is increasing rapidly because of the population's rising socioeconomic status and unique reproductive patterns. In this Review we present an overview of present control measures for breast cancer across China, and emphasise epidemiological and socioeconomic diversities and disparities in access to care for various subpopulations. We describe demographic differences between China and high-income countries, and also within geographical and socioeconomic regions of China. These disparities between China and high-income countries include younger age at onset of breast cancer; the unique one-child policy; lower rates of provision and uptake for screening for breast cancer; delays in diagnosis that result in more advanced stage of disease at presentation; inadequate resources; and a lack of awareness about breast cancer in the Chinese population. Finally, we recommend key measures that could contribute to improved health outcomes for patients with breast cancer in China.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24872111     DOI: 10.1016/S1470-2045(13)70567-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  504 in total

1.  Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation.

Authors:  Lei Fan; Peng Zhou; Qi Hong; Ao-Xiang Chen; Guang-Yu Liu; Ke-Da Yu; Zhi-Ming Shao
Journal:  Oncoimmunology       Date:  2019-03-30       Impact factor: 8.110

2.  Adjustment Disorder in Female Breast Cancer Patients: Prevalence and Its Accessory Symptoms.

Authors:  Hai-Yan Tang; Hui-Hua Xiong; Ling-Chao Deng; Yu-Xin Fang; Jun Zhang; Heng Meng
Journal:  Curr Med Sci       Date:  2020-05-30

3.  Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.

Authors:  Xiaoxia Wei; Hong Sun; Jie Zhuang; Xiuhua Weng; Bin Zheng; Qiwang Lin; Guifeng Zhang; Jiaqin Cai
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

4.  Does patient age affect the PPV3 of ACR BI-RADS Ultrasound categories 4 and 5 in the diagnostic setting?

Authors:  Yue Hu; Yaping Yang; Ran Gu; Liang Jin; Shiyu Shen; Fengtao Liu; Hongli Wang; Jingsi Mei; Xiaofang Jiang; Qiang Liu; Fengxi Su
Journal:  Eur Radiol       Date:  2018-01-04       Impact factor: 5.315

5.  MiR-519d-3p suppresses breast cancer cell growth and motility via targeting LIM domain kinase 1.

Authors:  Dengfeng Li; Hongming Song; Tianqi Wu; Dan Xie; Jiashu Hu; Junyong Zhao; Qiang Shen; Lin Fang
Journal:  Mol Cell Biochem       Date:  2017-11-29       Impact factor: 3.396

6.  The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients.

Authors:  Hyuna Sung; Changyuan Guo; Erni Li; Jing Li; Ruth M Pfeiffer; Jennifer L Guida; Renata Cora; Nan Hu; Joseph Deng; Jonine D Figueroa; Mark E Sherman; Gretchen L Gierach; Ning Lu; Xiaohong R Yang
Journal:  Int J Cancer       Date:  2019-01-07       Impact factor: 7.396

7.  STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.

Authors:  Ling Zhao; Qingyuan Zhang; Xin Luan; Xu Huang; Shu Zhao; Hong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

8.  Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

Authors:  Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

9.  Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer.

Authors:  Danmei Zhou; Kehan Ren; Jigang Wang; Hong Ren; Wenlin Yang; Wenjuan Wang; Qiong Li; Xiuping Liu; Feng Tang
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

10.  Cadmium exposure and the risk of breast cancer in Chaoshan population of southeast China.

Authors:  Lin Peng; Yiteng Huang; Jingwen Zhang; Yuhui Peng; Xueqiong Lin; Kusheng Wu; Xia Huo
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-20       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.